- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05486585
i-CBT Functional Gastrointestinal Disorders in Youth: the Impact of Negative Illness Understanding and Parental Illness Worries
Internet-delivered Psychological Treatment of Functional Gastrointestinal Disorders in Youth: the Impact of Negative Illness Understanding and Parental Illness Worries
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Functional gastrointestinal disorders (FGID) are common among children and adolescents. They affect quality of life, cause functional disability, school absence and high health care use.
Parental behavior can significantly influence the young person's perception of bodily symptoms, which are thought to be part of development and maintenance of symptoms FGID. So are cognitive biases which are distortions in attention, memory and interpretation.
The programs involve both the youth and their parents, which provides a unique possibility, to examine illness-related cognitive biases and the effectiveness of graded exposure in youths with FGID with an additional focus on parental distress and illness worries for treatment adherence and outcome.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Eva Nielsen, MD
- Phone Number: +45 23882426
- Email: eniels@rm.dk
Study Contact Backup
- Name: Karen Hansen Kallesøe, MD, PhD
Study Locations
-
-
-
Aarhus, Denmark
- Recruiting
- Aarhus University and Aarhus University Hospital, Child and Adolescents Psychiatry
-
Contact:
- Eva Skovslund Nielsen
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Child age: 8-12 years, adolescents: 13 - 17 years
- A primary diagnosis according to the ROME-IV criteria of one of the FGID sub-types: Irritable bowel syndrome (IBS) or functional abdominal pain not-otherwise-specified (FAP-NOS)
- The diagnosis should be documented by their regular physician in the somatic setting, and recommended routine medical investigations should be evaluated as normal or without clinical significance (include growth; blood samples including TSH, total IgA, IgA tissue transglutaminase, complete blood count, C-reactive protein analysis, liver enzymes; and fecal calprotectin)
- Stable dosage of FGID-related medication such as laxatives, anti-diarrheal medication or pain-modulating psychopharmacological medication during the past month.
Exclusion Criteria:
- Another disease that explains the symptoms;
- Severe psychiatric or social problems (e.g., high level of suicidal ideation or ongoing abuse);
- Ongoing psychological treatment;
- Insufficient language or computer skills (patients and parents);
- Severe family problems (e.g. child abuse, parental substance abuse or severe psychiatric illness, ongoing custody fight)
- School absence of more than 40% over the past month.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Children and Adolescents
30 children aged 8-12 years old and their parents, 30 adolescents aged 13-17 years old and their parents
|
The offered treatment will be the Danish versions of the Swedish i-CBT programs for children.
The child i-CBT program consists of 10 modules for the child and 10 for parents.
The adolescent i-CBT program consists of 10 modules for the adolescent and 5 modules for the parents.
Child and adolescents modules compose of exposure exercises for symptoms, behavioural analyses and affect labelling and are adjusted for the specific age group.
Parent modules aim at supporting parents in helping their child to engage in the challenging exposure exercises.
The family needs to select one parent to participate in the parent program.
The participants will be expected to use approximately 4 hours per week.
The programs will be delivered over ten weeks, and therapist support will be provided on a weekly basis.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in gastrointestinal symptoms assessed by PedsQL Gastro Symptom Scales
Time Frame: At baseline, after 5 weeks of treatment (mid-treatment), after 10 weeks of treatment (end-treatment) and 3-months after treatment (follow-up)]
|
The self-report questionnaire revised version of PedsQL Gastro Symptom Scales, with 9 items.
Answered on a 5 point scale from 0 ("never") to 4 ("almost always)
|
At baseline, after 5 weeks of treatment (mid-treatment), after 10 weeks of treatment (end-treatment) and 3-months after treatment (follow-up)]
|
Change in gastrointestinal symptoms rated by parents assessed by PedsQL Gastro Symptom Scales
Time Frame: At baseline, 5 weeks of treatment (mid-treatment), 10 weeks of treatment (end-treatment) and 3-months after treatment (follow-up)]
|
The parent-report questionnaire revised version of PedsQL Gastro Symptom Scales, with 9 items.
Answered on a 5 point scale from 0 ("never") to 4 ("almost always)
|
At baseline, 5 weeks of treatment (mid-treatment), 10 weeks of treatment (end-treatment) and 3-months after treatment (follow-up)]
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in Overall symptom load rated by parents measured by the parent-report questionnaire Children somatization inventory (parent report), short
Time Frame: At baseline, after 5 weeks of treatment (mid-treatment), after 10 weeks of treatment (end-treatment) and 3-months after treatment (follow-up)
|
The questionnaire consists of 24 items Answered on a 5 point scale from 0 ("not at all") to 4 ("a whole lot")
|
At baseline, after 5 weeks of treatment (mid-treatment), after 10 weeks of treatment (end-treatment) and 3-months after treatment (follow-up)
|
Changes in Illness perception rated by parents, measured by the parent-report questionnaire Illness perception regarding child's symptoms Questionnaire
Time Frame: At baseline, after 5 weeks of treatment (mid-treatment), after 10 weeks of treatment (end-treatment) and 3-months after treatment (follow-up)
|
A questionnaire with 11 items answered on a scale from 0 - 10
|
At baseline, after 5 weeks of treatment (mid-treatment), after 10 weeks of treatment (end-treatment) and 3-months after treatment (follow-up)
|
Changes in cognitive biases in interpretation and memory of stimuli related to gastrointestinal themes, leisure and school: Picture Task.
Time Frame: At baseline and 10-weeks of treatment (end of treatment)
|
Online experimental task with a picture task, with 15 pictures rated on emotional valence (0 negative, 100 positive), physical reaction (1 nota at all, 7 very much) and relatability to own life (1 not at all, 7 very much).
Pictures are then recalled and rated on emotional valence (0 negative, 100 positive) and physical reaction (1 nota at all, 7 very much).
Lastly pictures are recognised from unfamiliar pictures and rated on difficulty (1 not at all, 7 very much) and confidence (1 not at all, 7 very much).
|
At baseline and 10-weeks of treatment (end of treatment)
|
Changes in cognitive biases in interpretation and memory of stimuli related to gastrointestinal themes, leisure and school: Health Norms sorting Task.
Time Frame: At baseline and 10-weeks of treatment (end of treatment)
|
Online experimental task with FGID-specific version of the Health Norms Sorting Task, Participants sort 20 words as healthy or no longer healthy, recall as many words as possible and lastly recognise from previously unfamiliar words while rating on difficulty (1 not at all, 7 very much) and confidence (1 not at all, 7 very much).
|
At baseline and 10-weeks of treatment (end of treatment)
|
Changes in Quality of life assessed by the Pediatric Quality of Life Inventory
Time Frame: At baseline, 5 weeks of treatment (mid-treatment), 10 weeks of treatment (end-treatment) and 3-months after treatment (follow-up)
|
The self-report questionnaire Pediatric Quality of Life Inventory 8-12-year version for children, 13-18-year version for adolescents.
23 items, Answered on a 5 point scale from 0 ("never") to 4 ("almost always)
|
At baseline, 5 weeks of treatment (mid-treatment), 10 weeks of treatment (end-treatment) and 3-months after treatment (follow-up)
|
Changes in Quality of life rated by parents assessed by Pediatric Quality of Life Inventory
Time Frame: Time Frame: At baseline, 5 weeks of treatment (mid-treatment), 10 weeks of treatment (end-treatment) and 3-months after treatment (follow-up)
|
The parent-report questionnaire Pediatric Quality of Life Inventory for parents, (Parent report for children aged 8-12 years, and parent report for adolescents aged 13-17 years) .
23 items, Answered on a 5 point scale from 0 ("never") to 4 ("almost always)
|
Time Frame: At baseline, 5 weeks of treatment (mid-treatment), 10 weeks of treatment (end-treatment) and 3-months after treatment (follow-up)
|
Changes in Pain intensity measured by the self-report rating scale, Faces pain scale, revised
Time Frame: At baseline, after 5 weeks of treatment (mid-treatment), after 10 weeks of treatment (end-treatment) and 3-months after treatment (follow-up)
|
The scale consists of 6 faces representing least to most pain, and each face is connected to a number from 0 (no pain) - 10 (most pain), |
At baseline, after 5 weeks of treatment (mid-treatment), after 10 weeks of treatment (end-treatment) and 3-months after treatment (follow-up)
|
Changes in Pain intensity rated by parents Measured by the parent-report rating scale, Faces pain scale, revised
Time Frame: At baseline, 5 weeks of treatment (mid-treatment), 10 weeks of treatment (end-treatment) and 3-months after treatment (follow-up)]
|
The scale consists of 6 faces representing least to most pain, and each face is connected to a number from 0 (no pain) - 10 (most pain), |
At baseline, 5 weeks of treatment (mid-treatment), 10 weeks of treatment (end-treatment) and 3-months after treatment (follow-up)]
|
Changes in Overall symptom load measured by the self-report questionnaire Children somatization inventory , short (CSI)
Time Frame: At baseline, 5 weeks of treatment (mid-treatment), 10 weeks of treatment (end-treatment) and 3-months after treatment (follow-up)
|
The questionnaire consist of 24 items Answered on a 5 point scale from 0 ("not at all") to 4 ("a whole lot")
|
At baseline, 5 weeks of treatment (mid-treatment), 10 weeks of treatment (end-treatment) and 3-months after treatment (follow-up)
|
Changes in Depression symptoms measured by the self-report questionnaire Mood and Feelings Questionnaire short
Time Frame: At baseline, 10 weeks of treatment (end-treatment) and 3-months after treatment (follow-up)
|
The questionnaire consists of 13 items, answered on a 3 point scale: not true / sometimes true / true
|
At baseline, 10 weeks of treatment (end-treatment) and 3-months after treatment (follow-up)
|
Changes in General Anxiety symptoms measured by the self- report questionnaire Spence Children Anxiety Scale short
Time Frame: At baseline, 10 weeks of treatment (end-treatment) and 3-months after treatment (follow-up)
|
A 19 item-questionnaire answered on a 4 point scale from 0(never) to 3 (always)
|
At baseline, 10 weeks of treatment (end-treatment) and 3-months after treatment (follow-up)
|
Changes in General Anxiety rated by parents, Measured by the parent- report questionnaire Spence Children Anxiety Scale short, parent report
Time Frame: At baseline, 10 weeks of treatment (end-treatment) and 3-months after treatment (follow-up)]
|
A 19 item-questionnaire answered on a 4 point scale from 0(never) to 3 (always)
|
At baseline, 10 weeks of treatment (end-treatment) and 3-months after treatment (follow-up)]
|
Changes in Specific Gastrointestinal Anxiety, Measured by the self-report questionnaire Visceral Sensitivity Index -Short
Time Frame: At baseline, 5 weeks of treatment (mid-treatment), 10 weeks of treatment (end-treatment) and 3-months after treatment (follow-up)
|
A 7 item-questionnaire answered on a 5 point scale from 0 (don't agree at all) to 5 (totally agree)
|
At baseline, 5 weeks of treatment (mid-treatment), 10 weeks of treatment (end-treatment) and 3-months after treatment (follow-up)
|
Changes in Avoidance and control behaviour measured by the self-report questionnaire irritable bowel syndrome behavioural response questionnaire
Time Frame: At baseline, after 5 weeks of treatment (mid-treatment), after 10 weeks of treatment (end-treatment) and 3-months after treatment (follow-up)
|
A 11 item-questionnaire answered on a 7 point likert scale from 1(never) to 7(always)
|
At baseline, after 5 weeks of treatment (mid-treatment), after 10 weeks of treatment (end-treatment) and 3-months after treatment (follow-up)
|
Changes in Illness perception Measured by the self-report questionnaire Brief Illness perception Questionnaire
Time Frame: At baseline, 5 weeks of treatment (mid-treatment), 10 weeks of treatment (end-treatment) and 3-months after treatment (follow-up)
|
A questionnaire with 11 items answered on a scale from 0 - 10
|
At baseline, 5 weeks of treatment (mid-treatment), 10 weeks of treatment (end-treatment) and 3-months after treatment (follow-up)
|
Changes in Illness worry Measured by the self-report questionnaire Childhood Illness Attitude Scale
Time Frame: At baseline, 5 weeks of treatment (mid-treatment), 10 weeks of treatment (end-treatment) and 3-months after treatment (follow-up)
|
The fear-factor domain of the questionnaire is used, it consists of 11 items, answers: never, sometimes or always
|
At baseline, 5 weeks of treatment (mid-treatment), 10 weeks of treatment (end-treatment) and 3-months after treatment (follow-up)
|
Changes in Acceptance, measured by the self-report questionnaire Chronic pain Acceptance Questionnaire -adolescents
Time Frame: At baseline, 5 weeks of treatment (mid-treatment), 10 weeks of treatment (end-treatment) and 3-months after treatment (follow-up)
|
Two items from the self-report questionnaire Chronic pain Acceptance Questionnaire -adolescents are used.
2 selected items, answered on a 5-point scale from 0 (never true) to 4 (always true)
|
At baseline, 5 weeks of treatment (mid-treatment), 10 weeks of treatment (end-treatment) and 3-months after treatment (follow-up)
|
Changes in PARENTAL Illness Worry measured by the self-report The Health Anxiety by Proxy Scale (HAPYS) questionnaire
Time Frame: At baseline, 5 weeks of treatment (mid-treatment), 10 weeks of treatment (end-treatment) and 3-months after treatment (follow-up)
|
Parental illness worry for their child, measured by the self-report The questionnaire covers 26 items about health anxiety by proxy, rated on a five-point scale (from "not at all"/"never" to "a whole lot"/"most of the time").
And five items about the impact of the worries rated on a four-point scale (from "no" to "yes, severely").
|
At baseline, 5 weeks of treatment (mid-treatment), 10 weeks of treatment (end-treatment) and 3-months after treatment (follow-up)
|
Changes in PARENTAL Emotional distress measured by the self-report questionnaire Symptom Check List (SCL-8)
Time Frame: At baseline, after 5 weeks of treatment (mid-treatment), after 10 weeks of treatment (end-treatment) and 3-months after treatment (follow-up)
|
The questionnaire consists of 8 items answered on a 5 point scale from 0 (not at all) to 4 (a whole lot)
|
At baseline, after 5 weeks of treatment (mid-treatment), after 10 weeks of treatment (end-treatment) and 3-months after treatment (follow-up)
|
Changes in Adult Response to Child's Symptoms - PARENTS by the self-report questionnaire Adult Response to Children's Symptoms
Time Frame: At baseline, 5 weeks of treatment (mid-treatment), 10 weeks of treatment (end-treatment) and 3-months after treatment (follow-up)
|
Protect and Monitor scale from the the questionnaire Adult Response to Children's Symptoms used, 15 items answered on a 5 point scale from 0(never) to 4 (always)
|
At baseline, 5 weeks of treatment (mid-treatment), 10 weeks of treatment (end-treatment) and 3-months after treatment (follow-up)
|
Changes in School absence / Work absence parent
Time Frame: At baseline, 5 weeks of treatment (mid-treatment), 10 weeks of treatment (end-treatment) and 3-months after treatment (follow-up)
|
Question about Hours / Days missed from school/work last month.
Parental report for children aged 8-12 years, self-report for adolescents aged 13-17 years, self-report for parents
|
At baseline, 5 weeks of treatment (mid-treatment), 10 weeks of treatment (end-treatment) and 3-months after treatment (follow-up)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse events
Time Frame: At 10 weeks of treatment (End of treatment)
|
Open end questions.
Parents to children aged 8-12 years will answer on behalf of their children and adolescents aged 13-17 years will answer themselves.
|
At 10 weeks of treatment (End of treatment)
|
Treatment satisfaction by the self-report questionnaire Modified Experience of Service Questionnaire Modified Experience of Service Questionnaire
Time Frame: At 10 weeks of treatment (End of treatment)
|
10 items rated either true, partly true, not true or don't know and 3 open end questions
|
At 10 weeks of treatment (End of treatment)
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: Charlotte Ulrikka Rask, Professor, MD, PhD, Aarhus University and Aarhus University Hospital, Child and Adolescents Psychiatry
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- FGID pilot test
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Irritable Bowel Syndrome
-
ProgenaBiomeRecruitingIrritable Bowel Syndrome | Irritable Bowel Syndrome With Diarrhea | Irritable Bowel Syndrome With Constipation | Irritable Bowel Syndrome Characterized by Constipation | Irritable Bowel Syndrome Mixed | Irritable Bowel Syndrome Without Diarrhea | Irritable Bowel | Irritable Bowel Syndrome Aggravated and other conditionsUnited States
-
ClasadoCR2O B.V.RecruitingIrritable Bowel Syndrome | Irritable Bowel Syndrome - Constipation | Irritable Bowel Syndrome - Diarrhoea | Irritable Bowel Syndrome - MixedBelgium, Netherlands, United Kingdom
-
Istanbul Medipol University HospitalTepecik Training and Research Hospital; Bozyaka Training and Research Hospital and other collaboratorsRecruitingIrritable Bowel Syndrome | Irritable Bowel Syndrome With Diarrhea | Irritable Bowel Syndrome With Constipation | Irritable Bowel Syndrome MixedTurkey
-
Federal Stare Budgetary Scientific Institution,...I.M. Sechenov First Moscow State Medical University; RML INVEST, Torkhovsky...CompletedIrritable Bowel Syndrome | Irritable Bowel Syndrome With Diarrhea | Irritable Bowel Syndrome With Constipation | Irritable Bowel Syndrome MixedRussian Federation
-
University of California, Los AngelesCompletedIrritable Bowel Syndrome With Diarrhea | Irritable Bowel Syndrome With Mixed Bowel HabitsUnited States
-
University of ViennaCompleted
-
Thomayer University HospitalCharles University, Czech RepublicActive, not recruitingIrritable Bowel Syndrome With Diarrhea | Irritable Bowel Syndrome MixedCzechia
-
Shahid Beheshti University of Medical SciencesCompletedIrritable Bowel DiseaseIran, Islamic Republic of
-
Universidad Autonoma de ChihuahuaNot yet recruitingIrritable Bowel Syndrome | Constipation-predominant Irritable Bowel Syndrome | Diarrhea- Irritable Bowel Syndrome
-
Vasily IsakovRussian Science Foundation; Azbuka vkusa; Federal Research Centre of Nutrition...CompletedIrritable Bowel Syndrome With Constipation | Constipation-predominant Irritable Bowel SyndromeRussian Federation
Clinical Trials on Internet delivered cognitive behavioural therapy for functional gastrointestinal disorders
-
Aarhus University HospitalKarolinska InstitutetCompletedFunctional Gastrointestinal DisordersDenmark
-
Linkoeping UniversityOstergotland County Council, Sweden; Medical Research Council of Southeast...Completed
-
Lawson Health Research InstituteNot yet recruitingDepression | Stroke | Anxiety | Internet-Delivered Cognitive Behavioural Therapy
-
University of ReginaSaskatchewan Health Research FoundationCompleted
-
Institute of Mental Health, SingaporeCompleted
-
Lawson Health Research InstituteNot yet recruitingDepression | Anxiety | Spinal Cord Injuries | Caregiver Burnout | Internet-Delivered Cognitive Behavioural Therapy
-
Lawson Health Research InstituteRecruitingDepression | Anxiety | Mild Traumatic Brain Injury | Internet-Delivered Cognitive Behavioural TherapyCanada
-
Karolinska InstitutetRecruitingDepression | Anxiety Disorders | Insomnia | Psychiatric DisorderSweden
-
Institute of Mental Health, SingaporeRecruitingDepression | Anxiety DisordersSingapore
-
University of ReginaSaskatchewan Centre for Patient-Oriented ResearchCompletedDepression | Insomnia | AnxietyCanada